QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2

.
  • QIAstat-Dx Respiratory 2019-nCoV Panel rapidly differentiates novel coronavirus from 21 other pathogens implicated in serious respiratory syndromes
  • Panel being tested at four hospitals in China after initial evaluation on clinical samples by a leading Paris hospital
  • Adds to QIAGEN’s portfolio of molecular testing solutions to aid in global public health emergency

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation. The new kit detects the novel coronavirus SARS-CoV-2 and adds rapid Sample to Insight syndromic testing to QIAGEN’s portfolio of molecular testing solutions in the public health emergency. QIAGEN is also in the process of shipping QIAstat-Dx testing kits to public health institutions in other regions, including Europe, South-East Asia, and the Middle East.

Since January QIAGEN has been providing instruments and consumables to support detection of the virus in China and other markets. Official protocols for SARS-CoV-2 detection include QIAGEN extraction kits, reagents and instruments for real-time polymerase chain reaction (RT-PCR) workflows. Customers also are deploying QIAsymphony modular instruments and NeuMoDx integrated PCR systems to automate higher-throughput processing of their laboratory-developed tests for SARS-CoV-2.


“Our dedicated task force has moved very fast to develop and make available the QIAstat-Dx respiratory panel with SARS-CoV-2 detection. We are partnering closely with authorities and customers around the world to bring rapid, accurate diagnosis to the fight against this deadly infectious disease,” said Thierry Bernard, Interim CEO of QIAGEN and Senior Vice President, Head of the Molecular Diagnostics Business Area. “As we have in past health crises such as SARS and the swine flu, QIAGEN is working hard to deliver better, faster testing solutions for hospitals and public health institutions to aid in the effort to monitor and bring the outbreak under control. Our employees’ extraordinary response embodies QIAGEN’s core mission to make improvements in life possible.”

Please find the full press release here

Further information can be also found here

Firmenkontakt und Herausgeber der Meldung:

QIAGEN N.V.
Hulsterweg 82
NL5912 Venlo
Telefon: +49 (2103) 29-0
Telefax: +49 (2103) 29-22000
http://www.qiagen.com

Ansprechpartner:
John Gilardi
Investor Relations
Telefon: +49 (2103) 29-11711
Fax: +49 (2103) 29-11710
E-Mail: IR@qiagen.com
Dr. Thomas Theuringer
Public Relations
Telefon: +49 (2103) 29-11826
Fax: +49 (2103) 29-21826
E-Mail: pr@QIAGEN.com
Phoebe Loh
Investor Relations
Telefon: +49 (2103) 29-11457
E-Mail: phoebe.loh@qiagen.com
Robert Reitze
Public Relations
Telefon: +49 (2103) 29-11676
E-Mail: pr@QIAGEN.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel